UBS Group
CTNM

UBS Group’s Contineum Therapeutics CTNM Stock Holding History

UBS Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
130,642
-99,767
-43% -$1.31M ﹤0.01% 5060
2026
Q1 		$3.01M Buy
230,409
+31,020
+16% +$416K ﹤0.01% 4589
2025
Q4 		$2.28M Buy
199,389
+130,885
+191% +$1.49M ﹤0.01% 4853
2025
Q3 		$805K Buy
68,504
+60,839
+794% +$490K ﹤0.01% 5733
2025
Q2 		$30.4K Sell
7,665
-5,629
-42% -$24.5K ﹤0.01% 8149
2025
Q1 		$92.8K Sell
13,294
-11,587
-47% -$105K ﹤0.01% 7098
2024
Q4 		$365K Buy
24,881
+22,221
+835% +$352K ﹤0.01% 6062
2024
Q3 		$50.9K Buy
2,660
+553
+26% +$10.6K ﹤0.01% 6810
2024
Q2 		$37.1K Buy
+2,107
New +$33.9K ﹤0.01% 6916

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group's CTNM Position: Q2 2026 in Review

UBS Group reduced its Contineum Therapeutics (CTNM) stake by 43% in Q2 2026, selling an estimated $1.31M and leaving 130,642 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #5060.

UBS Group first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.01M in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • UBS Group held 130,642 shares of Contineum Therapeutics worth $2.14M as of Q2 2026.
  • UBS Group sold 99,767 Contineum Therapeutics shares in Q2 2026, an estimated $1.31M.
  • Contineum Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5060 holding.
  • UBS Group first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • UBS Group's Contineum Therapeutics position peaked at $3.01M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.